Live Markets
Wednesday, July 29, 2026·George Town, KY·29°·Partly Cloudy
Markets Open · NYSE·Newsletter·Masthead·
VOL. XII · NO. 117Established MMXIV · George Town, Grand CaymanAtlantic Edition · $4.50

The Cayman Journal

Finance · Business · Technology · Caribbean & Global Affairs
Markets · Healthcare

Bionano Genomics, Inc. (BNGO)

NCM · Medical Instruments & Supplies

$1.09+0.01 (+0.93%)Quote refreshed

Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires

Market Cap
$12.5M
P/E (TTM)
EPS
$-4.54
Div Yield
52W Range
$1.06–$5.50
Beta
1.62

Company overview

Next earnings: 2026-08-10(13d)

Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and purifies nucleic acid molecules. In addition, the company offers Saphyr, Stratys, and Bionano compute servers; and VIA software, which offers one solution for solutions for cytogenetics and molecular genetics. Further, it provides testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

Peers in Medical Instruments & Supplies

All in industry →

Recent press releases

April 2026

3 months agoDEF 14AHealthcare

Bionano Genomics, Inc. — DEF 14A Filing

BNGOBionano Genomics, Inc.

# 🧾 What This Document Is This is a **proxy statement**, a formal document that public companies must send to shareholders before a big vote. Think of it as an agenda and information packet for the company's annual meeting. It tells you what's being voted on, gives background info, and asks for yo

Read summaryView on SEC EDGAR

SEC filings

All filings →
1 recent filing shown in the timeline above. View all SEC filings →

Bionano Genomics, Inc. has no reported insider trades in the last 90 days.

Institutional holders

All holders →
As of 2025-06-30 · prior 2025-03-31

People at Bionano Genomics, Inc.

All people →

Quarterly financials

Full financials →
Revenue trend
03/25
$3.1M
NI -$3.1M
06/25
$6.7M
NI -$6.9M
09/25
$7.4M
NI -$8.5M
RevenueNI = Net Income
EPS trend (diluted)
Latest: $-1.59
Prior: $-1.99
Revenue sparkline